Abstract
A new treatment option for cataracts and advanced ARMD: the simultaneous intravitreal injection of anti-vascular endothelial growth factor and implantation of a high-add IOL. We believe major opportunities arise from a new subcategory in cataract surgery-called magnifying surgery (MAGS). Our case proves the potential of this brand-new technology.